The majority of patients with chronic lymphocytic leukemia (CLL) suffer a relapse following first-line therapy, while some patients do not respond to the initial treatment at all. Better treatment methods are being sought for these patients. In the past few years, the medicines ibrutinib (Imbruvica^®) and venetoclax (Venclyxto^®) were approved for the treatment of this patient group in Switzerland.

In the SAKK 34/17 trial we are treating patients with both active substances in combination to find out whether this improves the response and the course of the disease.

Further information on the trial can be found here.